https://www.mskcc.org/es/cancer-care/patient-education/medications/pediatric/ocrelizumab
Ocrelizumab: Pediatric Medication | Memorial Sloan Kettering Cancer Center
Esta información de UpToDate® Lexidrug™ le explica lo que debe saber sobre este medicamento, por ejemplo, para qué se usa, cómo tomarlo, sus efectos...
memorial sloan ketteringcancer centerocrelizumabpediatricmedication
https://pristineeyehospitals.com/know-your-medicines/medicines/ocrelizumab/
Ocrelizumab Eye Medicine: Uses, Brands & Dosage
Sep 20, 2026 - Ocrelizumab (Ocrevus) is used for Multiple sclerosis (incl. MS-related optic neuritis). Learn how it works, dosage, side effects and precautions.
ocrelizumabeyemedicineusesbrands
https://acnr.co.uk/nice-recommends-ocrevus%E2%96%BC-ocrelizumab-for-people-with-relapsing-remitting-multiple-sclerosis/
NICE recommends OCREVUS®▼ (ocrelizumab) for people with relapsing-remitting multiple sclerosis |...
Jan 9, 2025 - Significant milestone for people with multiple sclerosis as people with relapsing-remitting form gain access to new first-in-class treatment with twice-yearly...
relapsing remittingmultiple sclerosisnicerecommendsocrelizumab
https://eprf.ca/2022/09/02/gd-neda-individuals-experienced-a-rise-of-the-numbers-of-this-subset-after-ocrelizumab-treatment-p0/
Gd- NEDA individuals experienced a rise of the numbers of this subset after ocrelizumab treatment...
of thenedaindividualsexperiencedrise
https://www.roche.es/actualidad/notas-prensa-producto/2017/junio/ocrelizumab-reduce-progresion-esclerosis
Ocrelizumab reduce significativamente la... | Roche España
Ocrelizumab reduce significativamente la progresión de la esclerosis múltiple en sus formas en brotes y primaria progresiva.
la rocheocrelizumabreducesignificativamente
https://www.biospace.com/genentech-presents-new-six-year-ocrevus-ocrelizumab-data-which-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis
Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and...
Sep 13, 2019 - Genentech, a member of the Roche Group, announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed...
genentechpresentsnewsixyear
https://www.pw.nl/nieuws/geneesmiddelennieuws/2026-10/chmp-advies-ocrelizumab-ook-inzetbaar-bij-kinderen-vanaf-10?pw_search_cat_and_type=Herexamen
CHMP-advies: ocrelizumab ook inzetbaar bij kinderen vanaf 10 jaar | Pharmaceutisch Weekblad
Door een positief oordeel van de Europese geneesmiddelenbeoordelingscommissie CHMP is ocrelizumab (Ocrevus) breder toepasbaar.
chmpadviesocrelizumabookinzetbaar